Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology and infectious disease medicines. Its lead program, Endoxifen, is in Phase II clinical trials for breast cancer treatment and prevention. The company is also developing AT-H201, an inhalation therapy for improving lung function in severely ill COVID-19 patients, and AT-301, a drug candidate for nasal administration in COVID-19 patients. Additionally, Atossa Therapeutics is working on immunotherapy and chimeric antigen receptor therapy programs for breast cancer treatment. The company generates revenue through the development and potential commercialization of these innovative pharmaceutical products.

Products

• Endoxifen for breast cancer treatment and prevention

• AT-H201 for improving lung function in severely ill COVID-19 patients

• AT-301 for nasal administration in COVID-19 patients

• Immunotherapy and chimeric antigen receptor therapy programs for breast cancer treatment